These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 24019381)

  • 21. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
    Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
    Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
    Yunoki T; Tabuchi Y; Hayashi A; Kondo T
    Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8353-63. PubMed ID: 24366665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K; Becker S; Matthess Y
    Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PLK1 inhibitors: setting the mitotic death trap.
    Plyte S; Musacchio A
    Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
    Christoph DC; Schuler M
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1115-30. PubMed ID: 21806334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Polo-like kinase in cancer therapy.
    Degenhardt Y; Lampkin T
    Clin Cancer Res; 2010 Jan; 16(2):384-9. PubMed ID: 20068088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.
    Kannan S; Aitken MJL; Herbrich SM; Golfman LS; Hall MG; Mak DH; Burks JK; Song G; Konopleva M; Mullighan CG; Chandra J; Zweidler-McKay PA
    Mol Cancer Ther; 2019 Sep; 18(9):1615-1627. PubMed ID: 31227645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
    Li X; Tao Z; Wang H; Deng Z; Zhou Y; Du Z
    Exp Cell Res; 2020 Nov; 396(1):112261. PubMed ID: 32896567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
    Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
    Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
    Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
    Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma.
    Wu M; Wang Y; Yang D; Gong Y; Rao F; Liu R; Danna Y; Li J; Fan J; Chen J; Zhang W; Zhan Q
    EBioMedicine; 2019 Mar; 41():244-255. PubMed ID: 30876762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
    Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
    Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
    Zhong H; Xin S; Zhao Y; Lu J; Li S; Gong J; Yang Z; Lin S
    Mol Biosyst; 2010 Aug; 6(8):1463-8. PubMed ID: 20625580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
    Cheng MW; Wang BC; Weng ZQ; Zhu XW
    Acta Histochem; 2012 Sep; 114(5):503-9. PubMed ID: 22000864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
    Beria I; Ballinari D; Bertrand JA; Borghi D; Bossi RT; Brasca MG; Cappella P; Caruso M; Ceccarelli W; Ciavolella A; Cristiani C; Croci V; De Ponti A; Fachin G; Ferguson RD; Lansen J; Moll JK; Pesenti E; Posteri H; Perego R; Rocchetti M; Storici P; Volpi D; Valsasina B
    J Med Chem; 2010 May; 53(9):3532-51. PubMed ID: 20397705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
    Choi M; Kim W; Cheon MG; Lee CW; Kim JE
    Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
    Rudolph D; Impagnatiello MA; Blaukopf C; Sommer C; Gerlich DW; Roth M; Tontsch-Grunt U; Wernitznig A; Savarese F; Hofmann MH; Albrecht C; Geiselmann L; Reschke M; Garin-Chesa P; Zuber J; Moll J; Adolf GR; Kraut N
    J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
    Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ
    Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.